{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:22:29Z","timestamp":1762503749956},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,10,17]],"date-time":"2010-10-17T00:00:00Z","timestamp":1287273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s11060-010-0435-y","type":"journal-article","created":{"date-parts":[[2010,10,15]],"date-time":"2010-10-15T23:28:56Z","timestamp":1287185336000},"page":"635-640","source":"Crossref","is-referenced-by-count":27,"title":["Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma"],"prefix":"10.1007","volume":"103","author":[{"given":"Kathrin","family":"Ostermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Pels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Kowoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Kuhnhenn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,17]]},"reference":[{"key":"435_CR1","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.2005.04.8819","volume":"24","author":"T Batchelor","year":"2006","unstructured":"Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24:1281\u20131288","journal-title":"J Clin Oncol"},{"key":"435_CR2","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/CAD.0b013e32832f4abe","volume":"20","author":"M Benesch","year":"2009","unstructured":"Benesch M, Siegler N, Hoff K, Lassay L, Kropshofer G, Muller H, Sommer C, Rutkowski S, Fleischhack G, Urban C (2009) Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Anticancer Drugs 20:794\u2013799","journal-title":"Anticancer Drugs"},{"key":"435_CR3","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/archneur.1995.00540330094020","volume":"52","author":"MC Chamberlain","year":"1995","unstructured":"Chamberlain MC, Kormanik P, Howell SB, Kim S (1995) Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 52:912\u2013917","journal-title":"Arch Neurol"},{"key":"435_CR4","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/cncr.24204","volume":"115","author":"JA Garcia-Marco","year":"2009","unstructured":"Garcia-Marco JA, Panizo C, Garcia ES, Deben G, Alvarez-Larran A, Barca EG, Sancho JM, Penarrubia MJ, Garcia-Cerecedo T, Garcia Vela JA (2009) Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 115:1892\u20131898","journal-title":"Cancer"},{"key":"435_CR5","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","volume":"24","author":"IT Gavrilovic","year":"2006","unstructured":"Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570\u20134574","journal-title":"J Clin Oncol"},{"key":"435_CR6","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.1999.17.10.3110","volume":"17","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, Phuphanich S, Rogers LR, Gutheil JC, Batchelor T, Lyter D, Chamberlain M, Maria BL, Schiffer C, Bashir R, Thomas D, Cowens W, Howell SB (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110\u20133116","journal-title":"J Clin Oncol"},{"key":"435_CR7","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00277-008-0546-0","volume":"87","author":"I Hilgendorf","year":"2008","unstructured":"Hilgendorf I, Wolff D, Junghanss C, Kahl C, Leithaeuser M, Steiner B, Casper J, Freund M (2008) Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation. Ann Hematol 87:1009\u20131012","journal-title":"Ann Hematol"},{"key":"435_CR8","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2006-08-043646","volume":"109","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, O\u2019Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA (2007) Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109:3214\u20133218","journal-title":"Blood"},{"key":"435_CR9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1015752331041","volume":"57","author":"KA Jaeckle","year":"2002","unstructured":"Jaeckle KA, Batchelor T, O\u2019Day SJ, Phuphanich S, New P, Lesser G, Cohn A, Gilbert M, Aiken R, Heros D, Rogers L, Wong E, Fulton D, Gutheil JC, Baidas S, Kennedy JM, Mason W, Moots P, Russell C, Swinnen LJ, Howell SB (2002) An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 57:231\u2013239","journal-title":"J Neurooncol"},{"key":"435_CR10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ana.21824","volume":"67","author":"A Juergens","year":"2010","unstructured":"Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, Schmidt-Wolf IG, Schlegel U (2010) Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 67:182\u2013189","journal-title":"Ann Neurol"},{"key":"435_CR11","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1200\/JCO.1993.11.11.2186","volume":"11","author":"S Kim","year":"1993","unstructured":"Kim S, Chatelut E, Kim JC, Howell SB, Cates C, Kormanik PA, Chamberlain MC (1993) Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 11:2186\u20132193","journal-title":"J Clin Oncol"},{"key":"435_CR12","first-page":"397","volume":"3","author":"M Kripp","year":"2008","unstructured":"Kripp M, Hofheinz RD (2008) Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine. Int J Nanomed 3:397\u2013401","journal-title":"Int J Nanomed"},{"key":"435_CR13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11060-009-9892-6","volume":"95","author":"A Lassaletta","year":"2009","unstructured":"Lassaletta A, Lopez-Ibor B, Mateos E, Gonzalez-Vicent M, Perez-Martinez A, Sevilla J, Diaz MA, Madero L (2009) Intrathecal liposomal cytarabine in children under 4\u00a0years with malignant brain tumors. J Neurooncol 95:65\u201369","journal-title":"J Neurooncol"},{"key":"435_CR14","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1080\/10428190701573232","volume":"48","author":"B McClune","year":"2007","unstructured":"McClune B, Buadi FK, Aslam N, Przepiorka D (2007) Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. Leuk Lymphoma 48:1849\u20131851","journal-title":"Leuk Lymphoma"},{"key":"435_CR15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1474-4422(09)70091-2","volume":"8","author":"PG Morris","year":"2009","unstructured":"Morris PG, Abrey LE (2009) Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 8:581\u2013592","journal-title":"Lancet Neurol"},{"key":"435_CR16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1023\/A:1006206602918","volume":"43","author":"DF Nelson","year":"1999","unstructured":"Nelson DF (1999) Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol 43:241\u2013247","journal-title":"J Neurooncol"},{"key":"435_CR17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11060-008-9712-4","volume":"91","author":"H Pels","year":"2009","unstructured":"Pels H, Juergens A, Glasmacher A, Schulz H, Engert A, Linnebank M, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Lamprecht M, Hau P, Deckert M, Fimmers R, Bangard C, Schmidt-Wolf IG, Schlegel U (2009) Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol 91:299\u2013305","journal-title":"J Neurooncol"},{"key":"435_CR18","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1200\/JCO.2003.04.056","volume":"21","author":"H Pels","year":"2003","unstructured":"Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U (2003) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21:4489\u20134495","journal-title":"J Clin Oncol"},{"key":"435_CR19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11060-006-9218-x","volume":"81","author":"S Phuphanich","year":"2007","unstructured":"Phuphanich S, Maria B, Braeckman R, Chamberlain M (2007) A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 81:201\u2013208","journal-title":"J Neurooncol"},{"key":"435_CR20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/BF02710168","volume":"7","author":"A Rueda Dominguez","year":"2005","unstructured":"Rueda Dominguez A, Olmos Hidalgo D, Viciana Garrido R, Torres Sanchez E (2005) Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis. Clin Transl Oncol 7:232\u2013238","journal-title":"Clin Transl Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-010-0435-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-010-0435-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-010-0435-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T15:02:21Z","timestamp":1559746941000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-010-0435-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,17]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["435"],"URL":"https:\/\/doi.org\/10.1007\/s11060-010-0435-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,17]]}}}